Pulse Biosciences enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma

Reuters

03/12

<a href="https://laohu8.com/S/PLSE">Pulse Biosciences</a> enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma

Pulse Biosciences reported the first patient enrollments in a multicenter, first-in-human feasibility study evaluating the nPulse Vybrance Percutaneous Electrode System for treating T1N0M0 papillary thyroid microcarcinoma. The prospective study plans to enroll 30 patients across two sites and includes tumors smaller than 1.5 cm. Initial procedures were completed at Sarasota Memorial Health Care System and UT MD Anderson Cancer Center, with Ralph P. Tufano and Victoria Banuchi involved in the first cases. The device is being evaluated for thyroid cancer use under an FDA Investigational Device Exemption, and no study results were reported in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603120700BIZWIRE_USPR_____20260312_BW036459) on March 12, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2618136354"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618136354\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618136354?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618136354","market":"nz","top_or_hot":-1,"title":"Pulse Biosciences enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLSE\">Pulse Biosciences</a> enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pulse Biosciences reported the first patient enrollments in a multicenter, first-in-human feasibility study evaluating the nPulse Vybrance Percutaneous Electrode System for treating T1N0M0 papillary thyroid microcarcinoma. The prospective study plans to enroll 30 patients across two sites and includes tumors smaller than 1.5 cm. Initial procedures were completed at Sarasota Memorial Health Care System and UT MD Anderson Cancer Center, with Ralph P. Tufano and <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a> Banuchi involved in the first cases. The device is being evaluated for thyroid cancer use under an FDA Investigational Device Exemption, and no study results were reported in the announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603120700BIZWIRE_USPR_____20260312_BW036459) on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pulse Biosciences enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPulse Biosciences enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PLSE\">Pulse Biosciences</a> enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pulse Biosciences reported the first patient enrollments in a multicenter, first-in-human feasibility study evaluating the nPulse Vybrance Percutaneous Electrode System for treating T1N0M0 papillary thyroid microcarcinoma. The prospective study plans to enroll 30 patients across two sites and includes tumors smaller than 1.5 cm. Initial procedures were completed at Sarasota Memorial Health Care System and UT MD Anderson Cancer Center, with Ralph P. Tufano and <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a> Banuchi involved in the first cases. The device is being evaluated for thyroid cancer use under an FDA Investigational Device Exemption, and no study results were reported in the announcement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603120700BIZWIRE_USPR_____20260312_BW036459) on March 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL7j2DZQ:1","article_id":"2618136354","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618136354","pubTimestamp":1773313243,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pulse Biosciences enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma. Pulse Biosciences reported the first patient enrollments in a multicenter, first-in-human feasibility study evaluating the nPulse Vybrance Percutaneous Electrode System for treating T1N0M0 papillary thyroid microcarcinoma. The prospective study plans to enroll 30 patients across two sites and includes tumors smaller than 1.5 cm. Initial procedures were completed at Sarasota Memorial Health Care System and UT MD Anderson Cancer Center, with Ralph P. Tufano and Victoria Banuchi involved in the first cases. The device is being evaluated for thyroid cancer use under an FDA Investigational Device Exemption, and no study results were reported in the announcement.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","PLSE":"Pulse Biosciences, Inc."},"translate_title":"Pulse Biosciences招募首批患者参加nPulse Vybrance系统治疗甲状腺乳头状微小癌的30人可行性研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLSE":0.9},"content_text":"Pulse Biosciences enrolls first patients in 30-person feasibility study of nPulse Vybrance system for papillary thyroid microcarcinoma\n    \n\n        Pulse Biosciences reported the first patient enrollments in a multicenter, first-in-human feasibility study evaluating the nPulse Vybrance Percutaneous Electrode System for treating T1N0M0 papillary thyroid microcarcinoma. The prospective study plans to enroll 30 patients across two sites and includes tumors smaller than 1.5 cm. Initial procedures were completed at Sarasota Memorial Health Care System and UT MD Anderson Cancer Center, with Ralph P. Tufano and Victoria Banuchi involved in the first cases. The device is being evaluated for thyroid cancer use under an FDA Investigational Device Exemption, and no study results were reported in the announcement.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202603120700BIZWIRE_USPR_____20260312_BW036459) on March 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}